Navigation Links
Many smokers fail to quit after cancer diagnosis

A new report says despite a growing body of evidence that continued smoking after a cancer diagnosis has substantial adverse effects on treatment effectiveness, overall survival, risk of other cancers, and quality of life, up to one-half of cancer patients who smoke continue to do so or relapse after trying to quit.

The report, published in the January 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, says smoking cessation is an underutilized tool in cancer management and that healthcare providers often fail to advise smokers to quit.

The health risks of smoking are well understood. Smoking is linked to many primary diseases, such as cancer and respiratory diseases. In patients diagnosed with cancer, smoking is also associated with poor treatment outcomes, according to recent investigations. Despite these risks, up to half of smokers with cancer continue to smoke or relapse. Treatment for this addiction has largely been focused on healthy smokers and is critically dependent on smoker motivation. The diagnosis of cancer, according to research, is a strong motivator for many smokers and thus, provides a window of opportunity to begin treatment for smoking addiction.

Led by Ellen R. Gritz, Ph.D., of The University of Texas M. D. Anderson Cancer Center in Houston, researchers reviewed the scientific literature to provide a comprehensive overview of smoking cessation and cancer, in particular, guidelines and evidence-based treatment for smoking addiction.

They found that the literature provides ample evidence that patients who quit smoking around the time of diagnosis have improved disease outcomes compared to those who continue to smoke. The efficacy of cancer treatments may be reduced in continuing smokers, side effects of treatment may be exacerbated, and survival rates are lower. Quality of life (QOL) is also better in nonsmokers. For example, multiple studies found that compared to nonsmokers, current
'"/>

Source:John Wiley & Sons, Inc.


Page: 1 2

Related biology news :

1. New MRI technique shows emphysema in asymptomatic smokers
2. Successful lung cancer surgery not enough to break nicotine dependence in many smokers
3. PET imaging shows young smokers quick benefit of quitting
4. Indicators for risk of heart disease are higher in passive smokers
5. Better health twice as likely for nonsmokers who live and work with smoking restrictions
6. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
7. Does vitamin C help prevent or treat the common cold? Maybe not, after all.
8. Stem cell treatment improves mobility after spinal cord injury
9. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
10. New type of rejection blocker protects kidneys after transplant
11. Hurricane aftermath: Infectious disease threats from common, not exotic, diseases

Post Your Comments:
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)... that keep weakened and flabby arteries from colla...nths, those stents are no longer needed -- once th...ry. Previously, doctors had no choice but to leave...Aviv University,s Department of Biomedical Enginee...form that carries drugs where they,re needed, then...
(Date:11/24/2009)...N ROUGE Antarctica has long held secrets of the e... recently, there has been very little information ...miles of ice for millions of years. Now, a team of... have been funded to the tune of $10 million doll... get to the bottom of things literally. These sci...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 1Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 3Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 4Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 5Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 1China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 2China Pharma Holdings Inc Announces SFDA Approval for Rosuvastatin Clinical Trials 49581 3
...n a mud flat at the edge of the Cocheco River, jus...ersity of New Hampshire,s Contaminated Sediments C...ted sediment in coastal waterways. , Rather than ...al feet of sand, they,ve created a patch black ge...ion in place. Over the next two years, UNH associa...
... is available in German . , Infectious proteins... of "mad cow" disease (BSE). The culprits are "inc...y proteins. The molecular bases for such prion dis...roteins infectious while others are not? A team he...aimon Sabat (University of Bordeaux, France) has e...
...f., June 16 Authernative, Inc., a,leading develop...management,technologies, announced today that it h...n (GSA) Information Technology Schedule contract, ...tive to sell its AuthGuard(R),user authentication ... Schedule contract, which represents Authernative,...
Other Biology News:UNH researchers test sediment-scrubbing technology in NH river 2UNH researchers test sediment-scrubbing technology in NH river 3Tracking prions 2Authernative Awarded GSA Schedule Contract 2Authernative Awarded GSA Schedule Contract 3
(Date:11/24/2009)...w York investment bank KTA Capital,s client Neuren...7 mil convertible note private placement with a U....as arranged by KTA Capital as Neuren,s exclusive p... New York (PRWEB) November 23, 2009 -- The ind... ("KTA Capital") has announced that its ...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...RNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ...ommercializingnovelpainmanagementtherapies,announc...veOfficer,isscheduledtopresentatthe21stAnnualPiper...09atTheNewYorkPalaceHotelinNewYork,NewYork. ,, ...r,willbeavailabletorespondtoquestionsduringthepres...
(Date:11/24/2009)...asbeenmetforpatientswithadvanced-stage,orrecurrent...wire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;...panyfocusedonendocrinetherapyandoncology,todayanno...rgetedcytotoxicpeptideconjugate,AEZS-108(formerlyA...lcancer.Inapersonalizedhealthcareapproach,thestudy...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...TON, July 29 Scimitar Equity, LLC issues a review...ard: VOQP), entitled, "510k,Application Submitted ...cta(TM) Focuses Milestones and Share Price Appreci...tp://www.scimitarequity.com ., VioQuest Pharmaceu...,dedicated to becoming a recognized leader in the ...
... CARLOS, Calif., July 29 Nuvelo, Inc.,(Nasdaq: N...st subject in a,single-center, Phase 1 trial of re...lead compound from its Wnt Therapeutics Program. T...ding dose (SAD) trial will,determine the safety, t...ous (IV) administration of NU206, in approximately...
... "As one of AFRA,s fou...ceive its accreditation," remarks Gregoire Le... "For more than 10 years our vision in the gl...n, JMV Aviation and BAR) has been to operate in a ... to our five locations in France as well as facili...
Other Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 2First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 3First Program Addressing Aircraft Industry Sustainability Awards Accreditation To Five Global Companies 4
RDF (R106-05) from European Collection of Cell Cultures (ECACC)
...The Brownlee Precision Model 440 incorporates four...rcuitry in a friendly easy-to-use instrument. Each...er, an 8-pole Bessel lowpass filter, a highpass fi...ols. A control knob sets the amplifier parameters ...
REK (R102-05) from European Collection of Cell Cultures (ECACC)
PCAEC (P300-05) from European Collection of Cell Cultures (ECACC)
Biology Products: